Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Article

sustainable development goals

SDG 03: Good Health and Well-being

publication date

January 1, 2022

webpage

Web of Science

published in

CANCER MANAGEMENT AND RESEARCH Journal

keywords

adverse drug reaction
metastatic castration-resistant prostate cancer
poly(ADP-ribose) polymerase inhibitors
rucaparib

start page

673

end page

686

volume

14